The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Advances in molecular biology have identified numerous targetable genetic alterations in non-small cell lung cancer (NSCLC).
• Personalized medicine approaches are transforming lung cancer treatment strategies.

Purpose of the Study:

• To provide an overview of the current lung cancer treatment landscape.
• To highlight targeted therapies for specific genetic mutations and rearrangements.
• To discuss the importance and methods of molecular marker testing.

Main Methods:

• Review of current targeted therapies for lung cancer.
• Explanation of genetic alterations including EGFR, ALK, BRAF, ROS1, NTRK, RET, MET, and KRAS.
• Description of various molecular testing modalities.

Main Results:

• Targeted therapies are available for specific molecular profiles in lung cancer.
• Key genetic alterations like EGFR and ALK rearrangements, and BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, are critical treatment targets.
• Diverse testing methods exist for identifying these molecular markers.

Conclusions:

• The lung cancer treatment paradigm has shifted towards precision medicine.
• Identifying specific molecular alterations through comprehensive testing is essential for optimal patient management.
• Targeted therapies offer improved outcomes for patients with specific genetic profiles.